产品
编 号：F182014
分子式：C19H20F3N3O4
分子量：411.38
分子式：C19H20F3N3O4
分子量：411.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 153808-85-6
产品详情
生物活性：
Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases.
体内研究：
Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats.Animal Model:Male Sprague-Dawley rats weighing 180-220 g
Dosage:9 mg/kg
Administration:I.g. once or twice daily for 14 consecutive days
Result:Enhanced the expression of hepatic CYP2E1 mRNA, inducing a 1.6-fold increase compared with that of control rats.The level of CYP2E1 protein in the hepatic microsomes was significantly higher than control group, 190% of that in control rats.
体外研究：
Cadrofloxacin against M.tuberculosis with a MIC50 of 0.25 μg/mL.Cadrofloxacin against Acinetobacter spp. and Stenotrophomonas (Xanthomonas) maltophilia with MIC90s of 0.03 and 2 μg/ml, respectively.Cadrofloxacin against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria spp. with MIC90s less than or equal to 0.06 μg/mL.Cadrofloxacin against members of the family Enterobacteriaceae with MIC90s of 0.015 to 16 μg/mL (median MIC90, 0.06 μg/mL).
Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases.
体内研究：
Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats.Animal Model:Male Sprague-Dawley rats weighing 180-220 g
Dosage:9 mg/kg
Administration:I.g. once or twice daily for 14 consecutive days
Result:Enhanced the expression of hepatic CYP2E1 mRNA, inducing a 1.6-fold increase compared with that of control rats.The level of CYP2E1 protein in the hepatic microsomes was significantly higher than control group, 190% of that in control rats.
体外研究：
Cadrofloxacin against M.tuberculosis with a MIC50 of 0.25 μg/mL.Cadrofloxacin against Acinetobacter spp. and Stenotrophomonas (Xanthomonas) maltophilia with MIC90s of 0.03 and 2 μg/ml, respectively.Cadrofloxacin against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria spp. with MIC90s less than or equal to 0.06 μg/mL.Cadrofloxacin against members of the family Enterobacteriaceae with MIC90s of 0.015 to 16 μg/mL (median MIC90, 0.06 μg/mL).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备